References:
1. Villano JL, Letarte N, Yu JM, Abdur S, and Bressler LR. 2012. Hematologic adverse events ssociated with Temozolomide. Cancer Chemother Pharmacol 69:107-13.
2. Villano JL, Collins CA, Manasanch EE, Ramaprasad C, and van Besien K. 2006. Aplastic anaemia in patient with glioblastoma multiforme treated with Temozolomide. Lancet Oncol 7:436-8.
3. Batchelor T. Initial treatment and prognosis of newly diagnosed glioblastoma in adults. In: Loeffler JS, Wen PY, editors. Temozolomide. USA: Wolters Kluwer, 2019.
4. Comez G, Sevinc A, Sever ON et al. 2010. An unusual case of aplastic anemia caused by Temozolomide. Case Rep Med 2010:975039.
5. Dixit S, Baker L, Walmsley V, and Hingorani M. 2012. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review. Anticancer Drugs 23:1099-106.
6. George BJ, Eichinger JB, and Richard TJ. 2009. A rare case of aplastic anemia caused by Temozolomide. South Med J 102:974-6.
7. Jalali R, Singh P, Menon H, and Gujral S. 2007. Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 85:105-7.
8. Kopecky J, Priester P, Slovacek L et al. 2010. Aplastic anemia as a cause of death in a patient with glioblastoma multiforme treated with Temozolomide. Strahlenther Onkol 186:452-7.
9. Nagane M, Nozue K, Shimizu S et al. 2009. Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma–analysis of O6-methylguanine-DNA methyltransferase status. J Neurooncol 92:227-32.
10. Oh J, Kutas GJ, Davey P, Morrison M, and Perry JR. 2010. Aplastic anemia with concurrent temozolomide treatment in a patient with glioblastoma multiforme. Curr Oncol 17:124-6.
11. Newton SL, Kalamaha K, and Fernandes HD. 2018. Temozolomide-induced Aplastic Anemia Treated with Eltrombopag and Granulocyte Colony Stimulating Factor: A Report of a Rare Complication. Cureus 10:e3329.
12. Montemurro N. 2020. Glioblastoma Multiforme and Genetic Mutations: The Issue Is Not Over Yet. An Overview of the Current Literature. J Neurol Surg A Cent Eur Neurosurg 81:64-70.
13. Chang SM, Parney IF, Huang W et al. 2005. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557-64.
14. Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, and Forsyth PA. 2002. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947-9.
15. Halani SH, Babu R, and Adamson DC. 2017. Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature. World Neurosurg 105:53-62.
16. Stupp R, Hegi ME, Mason WP et al. 2009. Effects of radiotherapy with concomitant and adjuvant Temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-66.
17. Young NS. 2002. Acquired aplastic anemia. Ann Intern Med 136:534-46.
18. Issaragrisil S, Kaufman DW, Anderson T et al. 2006. The epidemiology of aplastic anemia in Thailand. Blood 107:1299-307.
19. Kurtzman G, and Young N. 1989. Viruses and bone marrow failure. Baillieres Clin Haematol 2:51-67.
20. Olson TS. Aplastic anemia: Pathogenesis, clinical manifestations, and diagnosis. In: Mentzer WC, editor EVALUATION. USA: Wolters Kluwer, 2019.
21. Olson TS, and Dunbar CE. Treatment of aplastic anemia in adults. In: Larson RA, editor. USA: Wolters Kluwer, 2020.
22. Kourelis TV, Buckner JC, Gangat N, and Patnaik MM. 2015. Temozolomide induced bone marrow Suppression–A single institution outcome analysis and review of the literature. Am J Hematol 90:E183-4.
Figures and Tables:
Figure 1: Patients Hemoglobin (Hgb), Platelet count and Absolute neutrophil count (ANC) during the hospital stay.
Figure 2: Section of bone marrow trephine biopsy showing marked hypocellularity. Many of the remaining cells are plasma cells. H & E, 4x
Table 1. Reported cases of Temozolomide induced Aplastic Anemia (†M: Male, ‡F: Female, §AA: Aplastic Anemia, ¶ CRT: chemo-radiotherapy)